US3669968A - Trialkoxy quinazolines - Google Patents

Trialkoxy quinazolines Download PDF

Info

Publication number
US3669968A
US3669968A US39541A US3669968DA US3669968A US 3669968 A US3669968 A US 3669968A US 39541 A US39541 A US 39541A US 3669968D A US3669968D A US 3669968DA US 3669968 A US3669968 A US 3669968A
Authority
US
United States
Prior art keywords
amino
compound
trimethoxyquinazoline
compounds
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US39541A
Other languages
English (en)
Inventor
Hans-Jurgen E Hess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of US3669968A publication Critical patent/US3669968A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms

Definitions

  • This invention relates to various new and useful trialkoxyquinazoline compounds, and to their chemical method of preparation. More particularly, it is concerned with a novel series of 2-substituted-4-amino-6,7,8-trialkoxyquinazolines and their pharmaceutically acceptable acid addition salts, which are of especial value in medicine in view of their unique chemotherapeutic properties.
  • novel 6,7,8-trialkoxyquinazoline compounds are extremely useful as antihypertensive agents, despite the aforesaid teaching indicated above, particularly regarding the 8-monomethoxy derivatives. More specifically, the novel compounds of this invention are all 2- substituted-4-amino-6,7,8-trialkoxyquinazolines of the formula:
  • R is chosen from the group consisting of methyl and ethyl; and Z is a member selected from the group consisting of monoalkylamino and dialkylamino each having up to three carbon atoms in the alkyl moiety, mono(/3-hydroxyethyl)amino and di(B-hydroxyethyl)-amino, pyrrolidino, piperidino, homopiperidino and N-substituted piperazino ofthe formula:
  • R is chosen from the group consisting of alkoxy having from one to six carbon atoms, alkenyloxy having up to five carbon atoms and hydroxyalkoxy having from two to six carbon atoms, alkyl having from one to six carbon atoms, phenyl, naphthyl, fury] and thienyl.
  • R is defined as aforesaid and X is a halogen atom selected from the group consisting of chlorine and bromine, is treated with an appropriate amine base of the formula ZH, where Z is as previously defined, to form the desired 2-substituted-4-amino-6,7,8-trialkoxyquinazoline final product.
  • This particular reaction is normally carried out by using an excess of the amine base with respect to the required equimolar ratio, since this serves to shift the reaction equilibrium to the product side of the equation.
  • the excess amine can also function as a solvent for the reaction, with a preferred excess for these purposes being from about two to about ten moles of amine per one mole of 2-halo-4-amino-6,7,8-trialkoxyquinazoline.
  • a reaction-inert polar organic solvent may also be used for the reaction and this would ordinarily entail employment of a cyclic ether such as dioxane and tetrahydrofuran, or a lower dialkylsulfoxide such as 3 dimethyl and diethlsulfoxide, or a lower alkanol solvent like methanol, ethanol or isoamyl alcohol, etc.
  • N,N-dialkyl lower alkanoamide such as N,N-dimethylformamide, N,N- dimethylacetamide, N,N-diethylformamide and the like.
  • the temperature at which the reaction can be conducted varies widely within the range of from about 50 C. up to about 200 C. for a period of about I to about 12 hours.
  • a preferred reaction time and temperature for the process at hand would be about l-l50 C. for about 2-4 hours.
  • a sealed pressure bottle as the proper vessel in which to conduct the reaction.
  • pounds used as starting materials in the herein described process of this invention such as 2-chloro and 2-bromo-4- amino-6,7,S-trimethoxyquinazoline, are themselves new compounds which are prepared by treating the corresponding 2,4-
  • the 2-halo-4-amino-6,7,8-trialkoxyquinazoline base com- I of the desired intermediate is readily accomplished using conventional means, such as, for example, partial evaporation of the solvent from the reaction mixture until incipient crystallization takes place, followed by trituration of the resulting residue with water or by reprecipitation of said residue from dilute aqueous acid.
  • the 2,4dihalo-6,7,B-trialkoxyquinazolines are all new compounds obtained by essentially known methods, starting from the corresponding known 2-amino-3,4,5-trialkoxybenzoic acid and reacting the latter type compound with either sodium or potassium cyanate in an aqueous acidic medium, followed by cyclization with aqueous base to form the intermediate 6,7,8-trialkoxy- 2,4[1H,3H ⁇ -quinazolindione ring compound, which, in turn, then yields the correspond-mg novel 2,4-dihalo-6,7,8-trialkoxyquinoline on treatment with either phosphorus oxychloride or phosphorus oxybromide in accordance with the general procedure of F.H.S. Curd et al., as described in the Journal of the Chemical Society (London), 1948, p. 1759.
  • a preferred and alternate method of preparation simply involves treating the corresponding compounds where R is alkenyloxy, as obtained by the principal process of this invention, with water in the presence of at least a catalytic amount of concentrated sulfuric acid to form the desired secondary or tertiary alcohol, as the case may be, in accordance with the standard methods of organic chemistry.
  • a preferred temperature range for this reaction would normally be from about -20 C.
  • the 2-substituted-4-amino-6,7,8-tria.lkoxyquinazoline compounds of this invention are basic compounds, they are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must first be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the 2-substituted-4-amino-6,7,8-trialkoxyquinazoline base compound from the reaction mixture as a pharmaceuticaliy unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and thereafter, subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the 2-substituted-4-amino-6,7,8-trialkoxyquinazoline base compounds of this invention are readily prepared by treating the base compound with an equivalent amount of the chosen acid in an aqueous solution or in a suitable organic solvent, such as methanol or ethanol. Upon evaporation of the solvent, the desired solid salt is obtained.
  • the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned 2-substituted-4-amino-6,7,8-trialkoxyquinazoline base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluene-sulfonate and pamoate [i.e., 1,1- methylene-bis( 2-hydroxy-3-naphthoate)]salts.
  • non-toxic acid addition salts
  • the 2-substituted-4-amino-6,7,8- trialkoxyquinazoline compounds of the present invention are all readily adapted to therapeutic use as antihypertensive agents, particularly in view of their ability to lower the blood pressure of hypertensive subjects to a statistically significant degree.
  • 2-methyl-2-hydroxypropyl 4-(4-amino- 6,7,8-trimethoxyquinazolin-2-yl)piperazinel -carboxylate a typical and preferred agent of the present invention, has been found to lower the blood pressure of conscious hypertensive dogs to a statistically significant degree e.g., up to 42 mm. Hg.
  • the herein described 2-substituted4-amino-6,7,8-trialkoxyquinazoline anti-hypertensive agents can be administered to a hypertensive subject via either the oral or parenteral routes of administration.
  • these compounds are most desirably administered in doses ranging from about 10 mg. up to about 600 mg. per day, although variations will still necessarily occur depe.iding upon the weight of the subject being treated.
  • a dosage level that is in the range of from about 0.16 mg. to about 9.6 mg. per kg. of body weight per day is most desirably employed in order to achieve effective results, with a preferred oral range in man being about 2.5-5.0 mg./kg.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful or deleterious side effects to occur provided that such higher dose levels are first divided into several smaller doses that are to be administered throughout the day.
  • the novel compounds of the invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically-acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, aqueous suspensions, injectable solutions, elixirs, syrups, and the like.
  • Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc.
  • oral pharmaceutical compositions can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for just such a purpose.
  • the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 0.5 percent to about percent by weight of the total composition, i.e., in amounts which are sufficient to provide the desired unit dosage.
  • tablets containing various excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as starch and preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules; preferred materials in the connection would also include lactose or milk sugar, as well as high molecular weight polyethylene glycols.
  • the essential active ingredient therein may be combined with various sweetneing or flavoring agents, coloring matters or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • solutions of these particular 2-substituted-4-amino6,7,8-trialkoxyquinazolines in either sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions of the corresponding water-soluble, non-toxic mineral and organic acid addition salts previously enumerated.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufiicient saline or glucose.
  • PREPARATION A A solution consisting of 65.3 g. (0.805 mole) of potassium cyanate dissolved in 200 ml. of water was added with stirring, during the course of a -minute period, to a suspension of 112 g. (0.535mole) of 2-amino-3,4,5-trimethoxybenzoic acid [obtained by saponification, with 1N NaOH in methanolwater (4:1 by volume), of the corresponding known methyl ester] in 2.6 liters of water containing 46 ml. of glacial acetic acid, while maintaining the temperature of the mixture at ca. 30 C. throughout the course of the addition. The resulting reaction mixture was then stirred at this same temperature for 2 hours, followed by the subsequent addition of 746 mg.
  • PREPARATION B The procedure described in Preparation A is repeated except that 2-amino-3,4,5-triethoxybenzoic acid is the starting material employed in place of the corresponding trimethoxy acid.
  • the corresponding final product obtained is 6,7,8-triethoxy-2,4[1H, 3H]quinazolindione.
  • EXAMPLE I A mixture consisting of 70.0 g. (0.278 mole) of 6,7,8- trimethoxy-2,4-[ 1H, 3H]-quinazolindione (m.p. 259-262 C.) and 1,100 m1. of phosphorus oxychloride was heated to reflux with stirring for a period of 2 hours. At the end of this time, the resulting clear solution was concentrated under reduced pressure and the residue thus obtained was dissolved in ca. 750 ml. of chloroform. The chloroform solution was slowly poured, with stirring, into an excess of saturated aqueous sodium bicarbonate and the resulting mixture vigorously stirred until evolution of carbon dioxide gas virtually ceased.
  • the chloroform layer was then separated from the mixture and combined with two subsequent chloroform extracts (750 ml.) of the aqueous phase.
  • the combined chloroform extracts were then washed with water, dried over anhydrous sodium sulfate and filtered to give a dry organic filtrate that was subsequently concentrated under reduced pressure to yield 73.0
  • EXAMPLE VII A mixture consisting of 8.08 g. (0.030 mole) of 2-chloro-4- amino-6,7,S-triemthoxyquinazoline (m.p. 243-246 C.) and 5.88 g. (0.033 mole) of 2-methylallyl l-piperazinecarboxylate in 200 m1. of isoamyl alcohol was heated to reflux for a period of 75 minutes. The resulting mixture was then cooled and concentrated under reduced pressure to afford an amorphous residue, which was subsequently triturated with ethyl acetate. The residue thus obtained was recovered by means of filtration and washed with ethyl acetate to give, after air drying to constant weight, 12.6 g.
  • EXAMPLE VIII A stirred solution consisting of 24 ml. of concentrated sulfuric acid dissolved in an equal volume of water was cooled to ca. l2 C. and treated with 6.25 g. (0.015 mole) of 2-methylallyl 4-(4-amino-6,7,8-trimethoxyquinazolin-Z-yl)piperazine-1- carboxylate added in small portions, with stirring being maintained throughout the course of the addition at such a rate as to always keep the temperature of the reaction mixture below 20 C. The resulting mixture was then further stirred for 15 minutes,while at 18 C., to give a clear solution, which was subsequently stirred for an additional two hours at lO-15 C.
  • the aqueous solution thus obtained was then diluted with 150 ml. of ice-water and adjusted to a pH of ca. with 50 percent aqueous sodium hydroxide, while maintaining the temperature below 12 C. throughout this step.
  • the resulting alkaline mixture was next extracted with four 150 ml. portions of chloroform, and the chloroform extracts were combined, washed with water and then dried over anhydrous sodium sulfate. After removal of the drying agent by means of filtration and the organic solvent by means of evaporation under reduced pressure, there was ultimately obtained a white crystalline solid as residue.
  • the yield of product amounted to 6.0 g. and it melted at 15 l-l 15 C.
  • Example VII The procedure described in Example VII is employed once again to prepare the final products of Examples VII and IX-XI by merely using the appropriate 2-bromo-4-amino-6,7,8-trialkoxyquinazoline compound, in place of the corresponding 2- chloro compound, as proper starting material for the reaction.
  • the final product thus obtained i.e., the 2-substituted-4-amino-6,7,8-trialkoxyquinazoline compound
  • the final product thus obtained is found to be identical with that reported previously for the corresponding reaction in the aforesaid examples.
  • 2-bromo-4-amino-6,7,8-trimethoxyquinazoline and 2-methallyl l-piperazinecarboxylate react in this manner to afford 2-methallyl 4-(4-amino-6,7,8-trimethoxyquinazolin-2- yl)piperazine-l-carboxylate, identical in every respect with the product of Example VII.
  • EXAMPLE XIV The nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and parnoate [i.e., 1,1 -methylene-bis(2-hydroxy-3- naphthoate)]salts of each of the aforementioned 2-substituted-4-amino-6,7,8-trialkoxyquinazoline base compounds reported previously are each prepared by dissolving the proper molar amounts of the respective acid and base in separate portions of ethanol and then mixing the two solutions together, followed by the addition of diethyl ether to the resultant solution in order to effect precipitation of the desired acid addition salt therefrom.
  • EXAMPLE XV A dry solid pharmaceutical composition is prepared by blending the following materials together in the proportions by weight specified below:
  • a dry solid pharmaceutical composition is prepared by combining the following materials together in the proportions by weight indicated below:
  • EXAMPLE XVII The following 2-substituted-4-amino-6,7,8-trimethoxyquinazolines were tested for hypotensive activity in conscious hypertensive dogs by the procedure of Prioli and Winbury, as described in the Journal of Applied Physiology, Vol. 15, p. 323 (1960) and found to be effective at the indicated concentration levels by both the oral and intravenous routes.
  • the compounds were administered in the form of their hydrochloride salts and the blood pressure determinations were made just prior to and at frequent intervals after drug administration (e.g., at 2, 4 and 24 hours thereafter), using at least two or more dogs for the evaluation of each compound.
  • the activity is therefore expressed in terms of the observed range in reduction of blood pressure in mm. Hg in two or more dogs, while the concentration levels are reported as mgjkg. per dose.
  • R is chosen from the group consisting of methyl and ethyl; and Z is a member selected form the group consisting of monoalkylamino and dialkylamino each having up to three carbon atoms in the alkyl moiety, monoUS-hydroxyethyl)amino and di(fl-hydroxyethyl)amino, pyrrolidino, piperidino, homopiperidino and N-substituted piperazino of the formula:
  • R is chosen from the group consisting of alkoxy having from one to six carbon atoms, alkenyloxy having up to five carbon atoms and hydroxyalkoxy having from two to six carbon atoms, alkyl having from one to six carbon atoms, phenyl, naphthyl, furyl and thienyl.
  • R is furyl.
  • R is thienyl.
  • R is alkenyloxy having up to five carbon atoms.
  • R is alkoxy having from one to six carbon atoms.
  • R is hydroxyalkoxy having from two to six carbon atoms.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US39541A 1970-05-21 1970-05-21 Trialkoxy quinazolines Expired - Lifetime US3669968A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3954170A 1970-05-21 1970-05-21
US24086572A 1972-04-03 1972-04-03

Publications (1)

Publication Number Publication Date
US3669968A true US3669968A (en) 1972-06-13

Family

ID=26716233

Family Applications (2)

Application Number Title Priority Date Filing Date
US39541A Expired - Lifetime US3669968A (en) 1970-05-21 1970-05-21 Trialkoxy quinazolines
US00240865A Expired - Lifetime US3769286A (en) 1970-05-21 1972-04-03 Trialkoxy quinazolines

Family Applications After (1)

Application Number Title Priority Date Filing Date
US00240865A Expired - Lifetime US3769286A (en) 1970-05-21 1972-04-03 Trialkoxy quinazolines

Country Status (10)

Country Link
US (2) US3669968A (fr)
JP (1) JPS5268191A (fr)
AT (1) AT308120B (fr)
BE (1) BE766444A (fr)
CH (1) CH521353A (fr)
DE (2) DE2120495C2 (fr)
FR (1) FR2092154B1 (fr)
GB (1) GB1309835A (fr)
NL (1) NL178594C (fr)
SE (2) SE384211B (fr)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920636A (en) * 1972-10-30 1975-11-18 Eisai Co Ltd Quinazoline compounds
US3980650A (en) * 1972-05-05 1976-09-14 N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia 4-Amino-pyrimidine derivatives
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
DE2725019A1 (de) 1976-06-15 1977-12-22 Pfizer Verfahren zur herstellung substituierter aminochinazolinderivate und zwischenprodukte dafuer
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4101548A (en) * 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4171363A (en) * 1977-02-22 1979-10-16 Bristol-Myers Company 1,2,3-Thiadiazole process
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
US4377581A (en) * 1980-03-03 1983-03-22 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
US4435401A (en) 1980-12-29 1984-03-06 Pfizer Inc. 4-Amino-6,7-dimethoxy-2-(4-heteroaryl-piperazino)quinazoline antihypertensives
US4582832A (en) * 1984-10-09 1986-04-15 Pfizer Inc. Trimazosin as an anti-atherosclerosis agent
US5064833A (en) * 1989-05-10 1991-11-12 Smithkline Beecham Intercredit B.V. Substituted quinazoline derivatives for use in gastrointestinal diseases
US5576322A (en) * 1991-09-30 1996-11-19 Eisai Co., Ltd. Anti-ischemic 2,4-diaminoquinazolines
WO2004017964A1 (fr) 2002-08-19 2004-03-04 Pfizer Products Inc. Therapie de combinaison pour maladies hyperproliferatives
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20060019974A1 (en) * 2000-09-20 2006-01-26 Werner Mederski 4-Amino-quinazolines
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
US20060247272A1 (en) * 2004-09-23 2006-11-02 Pfizer Inc 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds
WO2007024945A1 (fr) 2005-08-25 2007-03-01 Novartis Ag Derives imidazolo condenses utilises pour inhiber l'aldosterone synthase et l'aromatase
WO2007062314A2 (fr) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Inhibiteurs de cetp heterocycliques
US20070213319A1 (en) * 2006-01-11 2007-09-13 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
WO2007105050A1 (fr) 2006-03-10 2007-09-20 Pfizer Products Inc. Dibenzylamines et leurs dérivés
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
WO2008070496A2 (fr) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company Inhibiteurs d'amino cetp étendus
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
US20080248035A1 (en) * 2005-11-08 2008-10-09 Ranbaxy Laboratories Pharmaceutical Combination
US20100056602A1 (en) * 2003-05-30 2010-03-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors
EP2392567A1 (fr) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Derives de benzothiazine et leurs utilisation comme modulateurs de lxr
WO2014170786A1 (fr) 2013-04-17 2014-10-23 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
WO2020150473A2 (fr) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Inhibiteurs de pcsk9 et leurs procédés d'utilisation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1383409A (en) * 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4102885A (en) * 1977-06-20 1978-07-25 Bristol-Myers Company Process for preparing 2,4-dihaloquinazolines
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
DK154082C (da) * 1977-11-05 1989-02-27 Pfizer Analogifremgangsmaade til fremstilling af 4-amino-6,7-dimethoxy-2-(piperazin-1-yl eller homopiperazin-1-yl)-quinazolinforbindelser eller farmaceutisk acceptable syreadditionssalte deraf
US4510307A (en) * 1980-08-20 1985-04-09 Asahi Kasei Kogyo Kabushiki Kaisha 6-Quinazolinesulfonyl derivatives and process for preparation thereof
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
US5859070A (en) * 1993-10-18 1999-01-12 Imperial Chemical Industries, Plc Catalytic process
EP1571146A4 (fr) * 2002-12-10 2010-09-01 Ono Pharmaceutical Co Composes heterocycliques contenant de l'azote et leur utilisation medicale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980650A (en) * 1972-05-05 1976-09-14 N.V. Koninklijke Pharmaceutische Fabrieken V/H Brocades-Stheeman En Pharmacia 4-Amino-pyrimidine derivatives
US3920636A (en) * 1972-10-30 1975-11-18 Eisai Co Ltd Quinazoline compounds
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
DE2725019A1 (de) 1976-06-15 1977-12-22 Pfizer Verfahren zur herstellung substituierter aminochinazolinderivate und zwischenprodukte dafuer
US4101548A (en) * 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4171363A (en) * 1977-02-22 1979-10-16 Bristol-Myers Company 1,2,3-Thiadiazole process
US4098788A (en) * 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4287341A (en) * 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
US4351940A (en) * 1980-03-03 1982-09-28 Pfizer Inc. Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines
US4377581A (en) * 1980-03-03 1983-03-22 Pfizer Inc. Chloro- and alkoxy-substituted-2,4-diaminoquinazolines
US4435401A (en) 1980-12-29 1984-03-06 Pfizer Inc. 4-Amino-6,7-dimethoxy-2-(4-heteroaryl-piperazino)quinazoline antihypertensives
US4582832A (en) * 1984-10-09 1986-04-15 Pfizer Inc. Trimazosin as an anti-atherosclerosis agent
US5064833A (en) * 1989-05-10 1991-11-12 Smithkline Beecham Intercredit B.V. Substituted quinazoline derivatives for use in gastrointestinal diseases
US5576322A (en) * 1991-09-30 1996-11-19 Eisai Co., Ltd. Anti-ischemic 2,4-diaminoquinazolines
US7547702B2 (en) * 2000-09-20 2009-06-16 Ortho-Mcneil Pharmaceutical, Inc. 4-amino-quinazolines
US20060019974A1 (en) * 2000-09-20 2006-01-26 Werner Mederski 4-Amino-quinazolines
WO2004017964A1 (fr) 2002-08-19 2004-03-04 Pfizer Products Inc. Therapie de combinaison pour maladies hyperproliferatives
US20100056602A1 (en) * 2003-05-30 2010-03-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors
US20110190296A1 (en) * 2003-05-30 2011-08-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors
US20110190369A1 (en) * 2003-05-30 2011-08-04 Ranbaxy Laboratories Limited Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors
US7923467B2 (en) 2003-05-30 2011-04-12 Ranbaxy Laboratories, Inc. Substituted pyrrole derivatives and their use as HMG-CO inhibitors
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity
US20060247272A1 (en) * 2004-09-23 2006-11-02 Pfizer Inc 4-Amino Substituted-2-Substituted-1,2,3,4-tetrahydroquinoline Compounds
WO2007024945A1 (fr) 2005-08-25 2007-03-01 Novartis Ag Derives imidazolo condenses utilises pour inhiber l'aldosterone synthase et l'aromatase
EP2270011A1 (fr) 2005-08-25 2011-01-05 Novartis AG Dérivés d'imidazole condensé pour l'inhibition d'aromatase
EP2256118A1 (fr) 2005-08-25 2010-12-01 Novartis AG Dérivés d'imidazole condensé pour l'inhibition d'aromatase
EP2392567A1 (fr) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Derives de benzothiazine et leurs utilisation comme modulateurs de lxr
US7956198B2 (en) 2005-11-08 2011-06-07 Ranbaxy Laboratories, Limited Pharmaceutical compositions
US8026377B2 (en) 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US20080287690A1 (en) * 2005-11-08 2008-11-20 Ranbaxy Laboratories Limited Process For (3R, 5R)-7-[2-(4-Fluorophenyl)-5-Isopropyl-3-Phenyl-4- [(4-Hydroxy Methyl Phenyl Amino) Carbonyl]-Pyrrol-1-Yl]-3,5-Dihydroxy-Heptanoic Acid Hemi Calcium Salt
US7671216B2 (en) 2005-11-08 2010-03-02 Ranbaxy Laboratories Limited Process for preparation of (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US20080248035A1 (en) * 2005-11-08 2008-10-09 Ranbaxy Laboratories Pharmaceutical Combination
US20090118520A1 (en) * 2005-11-08 2009-05-07 Ranbaxy Laboratories Limited Process for preparation of (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
WO2007062314A2 (fr) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Inhibiteurs de cetp heterocycliques
US20080058312A1 (en) * 2006-01-11 2008-03-06 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
US20070213319A1 (en) * 2006-01-11 2007-09-13 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c-Met activity
WO2007105050A1 (fr) 2006-03-10 2007-09-20 Pfizer Products Inc. Dibenzylamines et leurs dérivés
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
US20080153896A1 (en) * 2006-07-14 2008-06-26 Gyan Chand Yadav Polymorphic Forms of an HMG-CoA Reductase Inhibitor and Uses Thereof
WO2008070496A2 (fr) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company Inhibiteurs d'amino cetp étendus
WO2014170786A1 (fr) 2013-04-17 2014-10-23 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
WO2020150473A2 (fr) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP4470609A2 (fr) 2019-01-18 2024-12-04 Astrazeneca AB Inhibiteurs de pcsk9 et leurs procédés d'utilisation

Also Published As

Publication number Publication date
US3769286A (en) 1973-10-30
DE2120495A1 (de) 1971-12-02
SE384211B (sv) 1976-04-26
DE2167157C2 (de) 1982-06-09
FR2092154B1 (fr) 1975-01-17
JPS5439386B2 (fr) 1979-11-27
AT308120B (de) 1973-06-25
GB1309835A (en) 1973-03-14
DE2120495C2 (de) 1982-06-03
NL7106029A (fr) 1971-11-23
BE766444A (fr) 1971-10-29
NL178594C (nl) 1986-04-16
FR2092154A1 (fr) 1972-01-21
NL178594B (nl) 1985-11-18
SE400280B (sv) 1978-03-20
CH521353A (fr) 1972-04-15
JPS5268191A (en) 1977-06-06

Similar Documents

Publication Publication Date Title
US3669968A (en) Trialkoxy quinazolines
US3609152A (en) Certain 2-amino-3,4-dihydrogen-inazolin-4-ones and 4-thiones
DE69202243T2 (de) 2,4-Diaminochinazolin-Derivate, um die Antitumorwirkung zu erhöhen.
US3780040A (en) 2-substituted-3,4-dihydroquinazolines
US3551428A (en) New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines
US3971783A (en) 4-Aminoquinazoline derivatives as cardiac stimulants
EP0000220B1 (fr) Dihydrouraciles, procédé pour leur préparation et médicaments les contenant
EP0005828A1 (fr) Nouvelles dérivés de la phénylpipérazine substitués, médicaments les contenant et procédés pour leur préparation
DE69201559T2 (de) Pyrimidinderivate zur erhöhung der antitumoraktivität.
DE2916140A1 (de) 1,3-diphenyl-2-iminoimidazolidine und 1,3-diphenyl-2-iminohexahydropyrimidine, verfahren zu ihrer herstellung und solche enthaltende arzneimittel
DE2461802A1 (de) Pyrazinderivate
US3951983A (en) Phenoxypropanolpiperazines
US3301855A (en) Derivatives of 4-nu-(2-nu, nu-dimethylaminolower alkyl)-amino quinazoline
SU927111A3 (ru) Способ получени оксимэфиров или их солей
SU816403A3 (ru) Способ получени производных 4-амино-2-(пипЕРАзиН-1-ил)-или 4-АМиНО-2-(гОМОпипЕРАзиН-1-ил) ХиНАзОлиНАили иХ фАРМАцЕВТичЕСКи пРиЕМлЕМыХСОлЕй C КиСлОТАМи
EP0276057B1 (fr) Pipérazinylpyrimidines comme agents de blocage des récepteurs bêta-adrénergiques
US3745216A (en) Compositions and methods for producing hypotensive activity with imidazo and pyrimido(2,1-b)quinazoline compounds
US4590271A (en) 2,4-diamino-5-(substituted)pyrimidines, useful as antimicrobials
US4705787A (en) Quinazolinone derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
US3509141A (en) 2-amino-quinazolines
US3838122A (en) 2-heterocyclic-1,3-benzodiazepines
US3426017A (en) Sulfonylurea compounds
US3635966A (en) 6-substituted-indolo(1 2-c)quinazolines
GB1592453A (en) Aminoalkyl esters of carbarimidothioic acid and compositions having immunosuppressant activity
US3673177A (en) Substituted 4-(anilinomethylene)-3-galanthamaninones